安里申5mg治疗轻至中度阿尔茨海默病为期12周的多中心开放性临床评估  

A MULTI-CENTER CLINICAL EVALUATION OF ARICEPT (DONEPEZIL ) 5MG/ DAY FOR 12 WEEKS IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER DISEASE.

作　　者：蔡琰[1] 陈生弟[2] 余慧贞[2] 俞丽华[3] 吕传真[4] 张明园[5] 邵福源[6] 李文贤 

机构地区：[1]上海第二医科大学附属仁济医院神经内科,200001 [2]上海第二医科大学附属瑞金医院神经内科 [3]上海第二医科大学附属新华医院神经内科 [4]上海医科大学附属华山医院神经内科 [5]上海市精神卫生中心 [6]第二军医大学附属长征医院神经内科 [7]华东医院神经内科

出　　处：《老年医学与保健》2000年第3期129-131,共3页Geriatrics & Health Care

摘　　要：目的 评估为期１２周的安里申５ｍｇ治疗轻至中度阿尔茨海默病（ＡＤ）的安全性与有效性。方法　根据严格的诊断标准与病例入选与排除标准，选择ＭＭＳＥ１１～ ２４分的轻至中度的ＡＤ病例，进行５ｍｇ安里申每晚一次的治疗，持续１２周。应用ＭＭＳＥ，ＣＤＲ，ＡＤＬ评估疗效，并观察任何不良反应的发生。结果　　病例总数为６５例，经１２周治疗后，症状有明显改善者共８例（１２．３１％）；症状改善者３４例（５２．３１％）；症状无变化者１８例（２７．６９％）；症状继续进展加重者５例（７．６９％）。除１例有持续３天的恶心与胃纳差外，其余病例均未发生任何不良反应。结论 为期１２周的５ｍｇ安里申治疗其对症治疗有效率为６４．６２％，未见重大不良反应。安里申每日５ｍｇ为安全而具有一定疗效的ＡＤ对症治疗药物。Objective Clinical evaluation of efficacy and safety of a 12-week course of Aricept 5mg/day in the treatment of mild to moderate Alzheimer disease. Methods Adopting international diagnostic criteria of Alzheimer disease, with strict inclusion and exclusion criteria, cases with MMSE score 11 - 24 were selected for the trial. MMSE, CDR and ADL were used for efficacy assessment. Side-effects during the treatment course were recorded, with evaluation and follow-up. Results 65 cases were selected for treatment. 8 cases (12. 31 % ) were markedly improved, 34 cases (52 .31 % ) had improvements, 18 cases (27. 69% ) had no change, and 5 cases (7. 69 % ) worsened. Besides transient nausea and decrease of appetite lasting 3 days in 1 case, no other side-effects were observed in the remaining 64 cases. Conclusions Aricept is an effective and safe drug for the symptomatic treatment of Alzheimer disease.

关 键 词：安里申 临床评估 早老性痴呆 

分 类 号：R749.16[医药卫生—神经病学与精神病学]